磷酸化紅細(xì)胞生成素受體抗體產(chǎn)品介紹
2022-09-09 14:13 來(lái)源:上海遠(yuǎn)慕生物試劑
中文名稱 磷酸化紅細(xì)胞生成素受體抗體
英文名稱 phospho-EPO Receptor (Tyr368)
別 名 EPO Receptor (phospho Y368); p-EPO Receptor (phospho Y368); EPOR (phospho Y368); p-EPOR (phospho Y368); erythropoietin receptor; EPO R; EPO Receptor; Erythropoietin receptor precursor; EPOR_HUMAN; MGC138358.
供 應(yīng) 商 遠(yuǎn)慕生物
產(chǎn)品類型 磷酸化抗體
研究領(lǐng)域 腫瘤 免疫學(xué)
抗體來(lái)源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human, Mouse, Rat,
產(chǎn)品應(yīng)用 WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 磷酸化紅細(xì)胞生成素受體抗體(石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 56kDa
細(xì)胞定位 細(xì)胞膜 細(xì)胞外基質(zhì) 分泌型蛋白
性 狀 Lyophilized or Liquid
濃 度 1mg/1ml
免 疫 原 KLH conjugated synthesised phosphopeptide derived from human EPO Receptor around the phosphorylation site of Tyr368
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
磷酸化紅細(xì)胞生成素受體抗體產(chǎn)品介紹 background:
The erythropoietin receptor (EPOR) is a member of the cytokine receptor family. There are several isoforms including: EPOR-F (full length), EPOR-S (soluble form), and EPOR-T (truncated form). Upon erythropoietin (EPO) binding, the EPOR activates Jak2 tyrosine kinase which activates different intracellular pathways including: Ras/MAP kinase, phosphatidylinositol 3-kinase and STAT transcription factors. The stimulated EPOR appears to have a role in erythroid cell survival. Defects in the EPOR may produce erythroleukemia and familial erythrocytosis. A functional EPOR is found in the cardiovascular system, including endothelial cells and cardiomyocytes, and data suggest that the EPO/EPO receptor system plays an important role in cardiac function. In animal studies, treatment with EPO during ischemia/reperfusion in the heart has been shown to limit the infarct size and the extent of apoptosis.
Function:
Forms homodimers on EPO stimulation. The tyrosine-phosphorylated form interacts with several SH2 domain-containing proteins including LYN, the adapter protein APS, PTPN6, PTPN11, JAK2, PI3 kinases, STAT5A/B, SOCS3, CRKL. Interacts with INPP5D/SHIP1. The N-terminal SH2 domain of PTPN6 binds Tyr-454 and inhibits signaling through dephosphorylation of JAK2. APS binding also inhibits the JAK-STAT signaling. Binding to PTPN11, preferentially through the N-terminal SH2 domain, promotes mitogenesis and phosphorylation of PTPN11. Binding of JAK2 (through its N-terminal) promotes cell-surface expression. Interaction with the ubiquitin ligase NOSIP mediates EPO-induced cell proliferation. Interacts with ATXN2L.
Subcellular Location:
Cell membrane; Single-pass type I membrane protein.
Isoform EPOR-S: Secreted. Note=Secreted and located to the cell surface.
Tissue Specificity:
Erythroid cells and erythroid progenitor cells. Isoform EPOR-F is the most abundant form in EPO-dependent erythroleukemia cells and in late-stage erythroid progenitors. Isoform EPOR-S and isoform EPOR-T are the predominant forms in bone marrow. Isoform EPOR-T is the most abundant from in early-stage erythroid progenitor cells.
Similarity:
Belongs to the type I cytokine receptor family.
Type 1 subfamily. Contains 1 fibronectin type-III domain.